MoonLake Immunotherapeutics (MLTX)

NASDAQ: MLTX · IEX Real-Time Price · USD
50.23
+0.02 (0.04%)
At close: Mar 28, 2024, 4:00 PM
50.77
+0.54 (1.08%)
After-hours: Mar 28, 2024, 6:15 PM EDT
0.04%
Market Cap 3.16B
Revenue (ttm) n/a
Net Income (ttm) -44.08M
Shares Out 62.45M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,172,077
Open 50.31
Previous Close 50.21
Day's Range 48.70 - 52.92
52-Week Range 17.82 - 64.98
Beta 1.20
Analysts Strong Buy
Price Target 76.63 (+52.56%)
Earnings Date May 10, 2024

About MLTX

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2021
Employees 50
Stock Exchange NASDAQ
Ticker Symbol MLTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for MLTX stock is "Strong Buy." The 12-month stock price forecast is $76.63, which is an increase of 52.56% from the latest price.

Price Target
$76.63
(52.56% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

18 days ago - GlobeNewsWire

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody ® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

24 days ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10

4 weeks ago - GlobeNewsWire

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody ® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

4 weeks ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing t...

4 months ago - GlobeNewsWire

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody ® sonelokimab in active psoriatic arthritis

5 months ago - GlobeNewsWire

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody ® sonelokimab as a highly promising and differentiated therapeutic solution for H...

5 months ago - GlobeNewsWire

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody ® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology C...

6 months ago - GlobeNewsWire

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress

Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody ® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatolog...

6 months ago - GlobeNewsWire

MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11

MoonLake Immunotherapeutics to ho st a Capital Markets Day on Monday , September 11

7 months ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

ZUG, Switzerland, August 10, 2023 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflamm...

8 months ago - GlobeNewsWire

MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

MoonLake completes patient randomization ahead of         schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts

8 months ago - GlobeNewsWire

Exclusive: MoonLake Immunotherapeutics explores sale-sources

MoonLake Immunotherapeutics , a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter.

9 months ago - Reuters

MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares

MoonLake Immunotherapeutics Announces Pricin g of $ 40 0 Million Upsized Public Offering of Class A Ordinary Shares

9 months ago - GlobeNewsWire

MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering

9 months ago - GlobeNewsWire

MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa

MoonLake Immunot herapeutics achieves landmark milestone with positive Phase 2 results for Nanobody ® sonelokimab in hidradenitis suppurativa

9 months ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets Day held in April highlighted the differentiating features of sonelokimab and st...

11 months ago - GlobeNewsWire

MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply

ZUG, Switzerland, May 3, 2023 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, toda...

11 months ago - GlobeNewsWire

MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today

ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases,...

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa

MoonLake Immunotherapeutics com pletes patient enrol l ment and randomization ahead of schedule in a Phase 2 trial of the Nanobody ® sonelokimab in moderate-to-severe hidradenitis suppurativa

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody® sonelokimab in active psoriatic arthritis

MoonLake Immunotherapeutics screens first patient in Phase 2 study of the Nanobody ® sonelokimab in active psoriatic arthritis

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

MoonLake Immunotherapeu tics Reports Third Quarter 2022 Financial Results and Provides Recent Business Update

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics to initiate global Phase 2 study of the Nanobody® sonelokimab in patients with active psoriatic arthritis

MoonLake Immunotherapeutics to i nitiate g lobal Phase 2 s tudy of the Nanobody ® s onelokimab in p atients with active psoriatic arthritis

1 year ago - GlobeNewsWire

MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH

MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH

1 year ago - GlobeNewsWire